107650-22-6

Basic information

• Product Name: 6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER
• Synonyms: 6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER;METHYL 6-BROMO-4-INDOLECARBOXYLATE;Methyl 6-Bromoindole-4-carboxylate;Methyl 6-broMoindole-4-ca...;Methyl 6-broMo-1H-indole-4-carboxylate;1H-Indole-4-carboxylic acid, 6-broMo-, Methyl ester;6-BroMo-1H-indole-4-carboxylic acid Methyl ester;Methyl 6-bromo-1H-indole-4-carboxylate Methyl 6-bromoindole-4-carboxylate
• CAS NO: 107650-22-6
• Molecular Formula: C10H8BrNO2
• Molecular Weight: 254.08
• Product Categories: pharmacetical
• Mol File: 107650-22-6.mol

Chemical Properties

• Boiling Point: 382.6 °C at 760 mmHg
• Flash Point: 185.2 °C
• Appearance: /
• Density: 1.629
• Vapor Pressure: 4.68E-06mmHg at 25°C
• Refractive Index: 1.666
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.87±0.30(Predicted)
• CAS DataBase Reference: 6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER(107650-22-6)
• EPA Substance Registry System: 6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER(107650-22-6)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 107650-22-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-4-INDOLECARBOXYLIC ACID METHYL ESTER is used as a reactant for the synthesis of potent, selective chymase inhibitors. Chymase is a type of protease enzyme that plays a role in various physiological processes, including inflammation and blood pressure regulation. Inhibiting chymase activity can be beneficial in the treatment of conditions such as hypertension and asthma, where chymase-mediated processes contribute to disease pathology.
The compound's role in the synthesis of chymase inhibitors is due to its structural similarity to the substrate of chymase, allowing it to act as a competitive inhibitor. By incorporating this compound into the synthesis process, researchers can develop more effective and selective chymase inhibitors with potential therapeutic applications.

InChI:InChI=1/C10H8BrNO2/c1-14-10(13)8-4-6(11)5-9-7(8)2-3-12-9/h2-5,12H,1H3

Upstream product

• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 67-56-1 methanol 

Downstream Products

• 1244017-43-3 C₁₈H₁₃NO₂ 
• 1346576-38-2 methyl 6-bromo-1-(sec-butyl)-3-formyl-1H-indole-4-carboxylate 
• 1346576-39-3 methyl 6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylate 
• 1346576-37-1 methyl 6-bromo-1-(sec-butyl)-1H-indole-4-carboxylate 
• 1346575-80-1 methyl 6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate 
• 1346575-81-2 6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid 
• 1346575-34-5 6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide 
• 1346575-54-9 6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylic acid 
• 1346574-53-5 6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide 
• 1346574-59-1 6-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide 
• 1365986-83-9 6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid methyl ester 
• 1346574-54-6 (S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide 
• 1346574-55-7 (R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide 
• 1346574-57-9 GSK-126 

Relevant articles and documents

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

Development and Scale-up of Continuous Electrocatalytic Hydrogenation of Functionalized Nitro Arenes, Nitriles, and Unsaturated Aldehydes

Electrolysis flow reactors based on the filter-press architecture of redox flow batteries have proven to be effective and scalable toward the production of commercially relevant, pharmaceutical quantities of anilines (>500 kg/year) from halogen-, hydroxyl-, and carbonyl-substituted nitroarenes. Turbulent flow through the carbon felts on which the catalysts were supported facilitated scaling toward production levels because it conferred on the reactors scale-independent, plug flow-like residence time distributions and high mass transfer coefficients. Equipping the cells with microreference electrodes made it possible to transfer reaction conditions first developed in batch systems to the continuous flow reactors. The catalysts prepared by incipient wetness impregnation of metal salts into lightly oxidized carbon felt supports were readily generalizable.

SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to substituted benzene compounds and bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation

A series of AG014699 derivatives containing a novel scaffold of 2,3-dihydro-1H-[1,2]diazepino[4,5,6-cd]indole-1,4(6H)-dione were synthesized and evaluated for their inhibitory activities toward PARP-1 enzyme and two cell lines, MCF-7 cells and the BRCA1-deficient MDA-MB-436 cells. Our results demonstrated that of all AG014699 derivatives synthesized in this work, compounds 6 and 7 showed strong PARP-1 inhibitory activity (IC50 = 3.5 nM and 2.4 nM, respectively), only four and three times less potent than AG014699. Compound 6 also had significantly cell inhibitory activity against both MCF-7 cells (CC50 = 25.8 μM) and the BRCA1-deficient MDA-MB-436 cells (CC50 = 5.4 μM), nearly as good as AG014699, indicating that it can be a promising compound for further evaluation.

1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical co

METHOD OF TREATMENT

The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.